Koers Genocea Biosciences Inc Nasdaq
Aandelen
US3724271040
Biotechnologie & Medisch Onderzoek
Omzet 2020 | 1,36 mln. 1,26 mln. | Omzet 2021 | 1,64 mln. 1,52 mln. | Marktkapitalisatie | 66,64 mln. 61,77 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2020 | -43 mln. -39,86 mln. | Nettowinst (verlies) 2021 | -33 mln. -30,59 mln. | EV/omzet 2020 | 50,8 x |
Nettoliquiditeiten 2020 | 55,9 mln. 51,82 mln. | Nettoliquiditeiten 2021 | 19,96 mln. 18,51 mln. | EV/omzet 2021 | 28,4 x |
K/w-verhouding 2020 |
-2,18
x | K/w-verhouding 2021 |
-2,4
x | Werknemers | - |
Dividendrendement 2020 * |
-
| Dividendrendement 2021 |
-
| Vrij verhandelbaar | 100% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chief Tech/Sci/R&D Officer | 52 | 01-03-07 | |
Girish Aakalu
PRN | Corporate Officer/Principal | - | 10-12-18 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Ken Bate
CHM | Chairman | 73 | 11-09-14 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+16,59% | 44,87 mld. | |
-10,62% | 37,8 mld. | |
+40,49% | 37,61 mld. | |
+29,92% | 31,32 mld. | |
-9,78% | 27,4 mld. | |
+12,34% | 26,32 mld. | |
+41,53% | 14,07 mld. | |
+31,49% | 12,5 mld. | |
-7,40% | 11,23 mld. |